• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Celator Pharmaceuticals

edit

Celator Pharmaceuticals, Inc., a biopharmaceutical company, develops therapies to treat cancer. The company focuses on CombiPlex, a drug ratio technology platform that enables to the development of combination therapies. Its products include CPX-1 (Irinotecan HCI-Floxuridine), a treatment for colorectal cancer; and CPX-351 (Cytarabine-Daunorubicin), a treatment for acute myeloid leukemia (AML). Celator Pharmaceuticals, Inc. was formerly known as Celator Technologies, Inc. The company was founded in 2000 and is headquartered in Princeton, New Jersey.

Recent Milestones

edit

• 
  Celator Pharmaceuticals received $39.3M in Private Equity funding. (4/30/13)
  Posted 5/2/13 at 9:19pm via celatorpharma.com
• 
  Celator Pharmaceuticals received $20M in Series D funding. (9/1/10)
  Posted 9/2/10 at 6:13am via celatorpharma.com
• 
  Celator Pharmaceuticals added Scott Jackson as CEO.
  Posted 9/2/10 at 6:13am

Videos

Screenshots

edit

Sources

1. CELATOR® PHARMACEUTICALS RAISES $20 MILLION IN SERIES D FINANCING (celatorpharma.com) [edit]
2. CELATOR® PHARMACEUTICALS RAISES $32.5 MILLION COMPLETING A $39.3 MILLION PRIVATE PLACEMENT FINANCING (celatorpharma.com) [edit]